Subjective and cardiovascular effects of cocaine during treatment with amantadine and baclofen in combination

Erin Rotheram-Fuller, Richard De La Garza, James J. Mahoney, Steve Shoptaw, Thomas F. Newton

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

This study assessed the subjective and cardiovascular effects of relevant doses of cocaine administration during steady-state treatment of the combination of amantadine and baclofen compared to placebo. Participants included 8 healthy, male, cocaine-dependent, non-treatment-seeking individuals (age = 36.6 ± 5.9; 75% African American, 25% Caucasian; using cocaine for an average of 15.3 ± 6.5 years). Data were collected prior to and following double-blind intravenous administration of 0 mg, 20 mg, and 40 mg of cocaine. Data were collected at baseline, following 5 days of treatment with placebo, and again following 5 days of treatment with a combination of amantadine 100 mg t.i.d. and baclofen 30 mg t.i.d. counterbalanced for order of medication and placebo in a cross-over design. Results showed no significant alterations to cardiovascular variables (heart rate, systolic and diastolic blood pressure) from treatment using combination medication or placebo in the presence of cocaine. Self-rated "desire" for cocaine was significantly lower during cocaine administrations while participants were receiving treatment with amantadine-baclofen compared to infusions while taking placebo medication, although there was no difference in the intensity of cocaine-induced euphoria, or reduction in the likelihood to use cocaine if given access. Study findings support the safety of the amantadine-baclofen combination treatment for cocaine dependence.

Original languageEnglish (US)
Pages (from-to)205-210
Number of pages6
JournalPsychiatry Research
Volume152
Issue number2-3
DOIs
StatePublished - Aug 30 2007
Externally publishedYes

Fingerprint

Amantadine
Baclofen
Cocaine
Placebos
Therapeutics
Blood Pressure
Cocaine-Related Disorders
Intravenous Administration
African Americans
Cross-Over Studies
Heart Rate
Safety

Keywords

  • Amantadine
  • Baclofen
  • Cocaine
  • Pharmacotherapy
  • Phase I Clinical Trial

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry
  • Psychology(all)

Cite this

Subjective and cardiovascular effects of cocaine during treatment with amantadine and baclofen in combination. / Rotheram-Fuller, Erin; De La Garza, Richard; Mahoney, James J.; Shoptaw, Steve; Newton, Thomas F.

In: Psychiatry Research, Vol. 152, No. 2-3, 30.08.2007, p. 205-210.

Research output: Contribution to journalArticle

Rotheram-Fuller, Erin ; De La Garza, Richard ; Mahoney, James J. ; Shoptaw, Steve ; Newton, Thomas F. / Subjective and cardiovascular effects of cocaine during treatment with amantadine and baclofen in combination. In: Psychiatry Research. 2007 ; Vol. 152, No. 2-3. pp. 205-210.
@article{978d4d0f527b4963bf35bed213ce2fd9,
title = "Subjective and cardiovascular effects of cocaine during treatment with amantadine and baclofen in combination",
abstract = "This study assessed the subjective and cardiovascular effects of relevant doses of cocaine administration during steady-state treatment of the combination of amantadine and baclofen compared to placebo. Participants included 8 healthy, male, cocaine-dependent, non-treatment-seeking individuals (age = 36.6 ± 5.9; 75{\%} African American, 25{\%} Caucasian; using cocaine for an average of 15.3 ± 6.5 years). Data were collected prior to and following double-blind intravenous administration of 0 mg, 20 mg, and 40 mg of cocaine. Data were collected at baseline, following 5 days of treatment with placebo, and again following 5 days of treatment with a combination of amantadine 100 mg t.i.d. and baclofen 30 mg t.i.d. counterbalanced for order of medication and placebo in a cross-over design. Results showed no significant alterations to cardiovascular variables (heart rate, systolic and diastolic blood pressure) from treatment using combination medication or placebo in the presence of cocaine. Self-rated {"}desire{"} for cocaine was significantly lower during cocaine administrations while participants were receiving treatment with amantadine-baclofen compared to infusions while taking placebo medication, although there was no difference in the intensity of cocaine-induced euphoria, or reduction in the likelihood to use cocaine if given access. Study findings support the safety of the amantadine-baclofen combination treatment for cocaine dependence.",
keywords = "Amantadine, Baclofen, Cocaine, Pharmacotherapy, Phase I Clinical Trial",
author = "Erin Rotheram-Fuller and {De La Garza}, Richard and Mahoney, {James J.} and Steve Shoptaw and Newton, {Thomas F.}",
year = "2007",
month = "8",
day = "30",
doi = "10.1016/j.psychres.2006.03.012",
language = "English (US)",
volume = "152",
pages = "205--210",
journal = "Psychiatry Research",
issn = "0165-1781",
publisher = "Elsevier Ireland Ltd",
number = "2-3",

}

TY - JOUR

T1 - Subjective and cardiovascular effects of cocaine during treatment with amantadine and baclofen in combination

AU - Rotheram-Fuller, Erin

AU - De La Garza, Richard

AU - Mahoney, James J.

AU - Shoptaw, Steve

AU - Newton, Thomas F.

PY - 2007/8/30

Y1 - 2007/8/30

N2 - This study assessed the subjective and cardiovascular effects of relevant doses of cocaine administration during steady-state treatment of the combination of amantadine and baclofen compared to placebo. Participants included 8 healthy, male, cocaine-dependent, non-treatment-seeking individuals (age = 36.6 ± 5.9; 75% African American, 25% Caucasian; using cocaine for an average of 15.3 ± 6.5 years). Data were collected prior to and following double-blind intravenous administration of 0 mg, 20 mg, and 40 mg of cocaine. Data were collected at baseline, following 5 days of treatment with placebo, and again following 5 days of treatment with a combination of amantadine 100 mg t.i.d. and baclofen 30 mg t.i.d. counterbalanced for order of medication and placebo in a cross-over design. Results showed no significant alterations to cardiovascular variables (heart rate, systolic and diastolic blood pressure) from treatment using combination medication or placebo in the presence of cocaine. Self-rated "desire" for cocaine was significantly lower during cocaine administrations while participants were receiving treatment with amantadine-baclofen compared to infusions while taking placebo medication, although there was no difference in the intensity of cocaine-induced euphoria, or reduction in the likelihood to use cocaine if given access. Study findings support the safety of the amantadine-baclofen combination treatment for cocaine dependence.

AB - This study assessed the subjective and cardiovascular effects of relevant doses of cocaine administration during steady-state treatment of the combination of amantadine and baclofen compared to placebo. Participants included 8 healthy, male, cocaine-dependent, non-treatment-seeking individuals (age = 36.6 ± 5.9; 75% African American, 25% Caucasian; using cocaine for an average of 15.3 ± 6.5 years). Data were collected prior to and following double-blind intravenous administration of 0 mg, 20 mg, and 40 mg of cocaine. Data were collected at baseline, following 5 days of treatment with placebo, and again following 5 days of treatment with a combination of amantadine 100 mg t.i.d. and baclofen 30 mg t.i.d. counterbalanced for order of medication and placebo in a cross-over design. Results showed no significant alterations to cardiovascular variables (heart rate, systolic and diastolic blood pressure) from treatment using combination medication or placebo in the presence of cocaine. Self-rated "desire" for cocaine was significantly lower during cocaine administrations while participants were receiving treatment with amantadine-baclofen compared to infusions while taking placebo medication, although there was no difference in the intensity of cocaine-induced euphoria, or reduction in the likelihood to use cocaine if given access. Study findings support the safety of the amantadine-baclofen combination treatment for cocaine dependence.

KW - Amantadine

KW - Baclofen

KW - Cocaine

KW - Pharmacotherapy

KW - Phase I Clinical Trial

UR - http://www.scopus.com/inward/record.url?scp=34547684290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547684290&partnerID=8YFLogxK

U2 - 10.1016/j.psychres.2006.03.012

DO - 10.1016/j.psychres.2006.03.012

M3 - Article

C2 - 17449110

AN - SCOPUS:34547684290

VL - 152

SP - 205

EP - 210

JO - Psychiatry Research

JF - Psychiatry Research

SN - 0165-1781

IS - 2-3

ER -